Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
ABIO's Cash to Debt is ranked higher than
88% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. ABIO: No Debt )
ABIO' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: 7.47
M-Score: -3.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -49.89
ABIO's ROE (%) is ranked higher than
63% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. ABIO: -49.89 )
ABIO' s 10-Year ROE (%) Range
Min: -828.55   Max: -17.89
Current: -49.89

-828.55
-17.89
ROA (%) -47.22
ABIO's ROA (%) is ranked higher than
61% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. ABIO: -47.22 )
ABIO' s 10-Year ROA (%) Range
Min: -134.31   Max: -8.06
Current: -47.22

-134.31
-8.06
ROC (Joel Greenblatt) (%) -35863.64
ABIO's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. ABIO: -35863.64 )
ABIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26692.31   Max: -42.86
Current: -35863.64

-26692.31
-42.86
EBITDA Growth (%) -48.00
ABIO's EBITDA Growth (%) is ranked higher than
54% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ABIO: -48.00 )
ABIO' s 10-Year EBITDA Growth (%) Range
Min: -73.4   Max: 17.3
Current: -48

-73.4
17.3
EPS Growth (%) -44.10
ABIO's EPS Growth (%) is ranked higher than
57% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. ABIO: -44.10 )
ABIO' s 10-Year EPS Growth (%) Range
Min: -72.5   Max: 24.5
Current: -44.1

-72.5
24.5
» ABIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ABIO Guru Trades in Q2 2013

Jim Simons 14,800 sh (+3.27%)
» More
Q3 2013

ABIO Guru Trades in Q3 2013

Jim Simons 93,770 sh (+533.58%)
» More
Q4 2013

ABIO Guru Trades in Q4 2013

Jim Simons 615,182 sh (+556.05%)
» More
Q1 2014

ABIO Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.39
ABIO's P/B is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. ABIO: 1.39 )
ABIO' s 10-Year P/B Range
Min: 0.01   Max: 60.51
Current: 1.39

0.01
60.51
EV-to-EBIT -0.64
ABIO's EV-to-EBIT is ranked higher than
75% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ABIO: -0.64 )
ABIO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.64

Current Ratio 16.17
ABIO's Current Ratio is ranked higher than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. ABIO: 16.17 )
ABIO' s 10-Year Current Ratio Range
Min: 0.22   Max: 27.54
Current: 16.17

0.22
27.54
Quick Ratio 16.17
ABIO's Quick Ratio is ranked higher than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. ABIO: 16.17 )
ABIO' s 10-Year Quick Ratio Range
Min: 0.22   Max: 27.54
Current: 16.17

0.22
27.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.49
ABIO's Price/Net Cash is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. ABIO: 1.49 )
ABIO' s 10-Year Price/Net Cash Range
Min: 0.66   Max: 285.92
Current: 1.49

0.66
285.92
Price/Net Current Asset Value 1.49
ABIO's Price/Net Current Asset Value is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. ABIO: 1.49 )
ABIO' s 10-Year Price/Net Current Asset Value Range
Min: 0.66   Max: 195.92
Current: 1.49

0.66
195.92
Price/Tangible Book 1.39
ABIO's Price/Tangible Book is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. ABIO: 1.39 )
ABIO' s 10-Year Price/Tangible Book Range
Min: 0.53   Max: 39.01
Current: 1.39

0.53
39.01
Forward Rate of Return (Yacktman) -115.50
ABIO's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ABIO: -115.50 )
ABIO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -115.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HQ13.Germany
ARCA biopharma, Inc., was originally incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, Nuvelo merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, it was reincorporated from Nevada to Delaware. On January 27, 2009, in connection with the Merger with ARCA Colorado described above, Nuvelo changed its name to ARCA biopharma, Inc. Its main offices are located in Broomfield, Colorado. It is a biopharmaceutical company whose focus is developing genetically-targeted therapies for cardiovascular diseases. Its product candidate, Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment of atrial fibrillation (AF) in patients with heart failure (HF). The company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing. The company outsources all manufacturing and analytical testing of the Gencaro API and drug product. The company is contracted with Groupe Novasep to complete the drug substance registration batches required for the Gencaro NDA. These batches were successful, and the resulting drug substance was used to supply the drug product registration campaign. For drug product production, the company has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. The Company faces competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Governmental authorities in the U.S. at the federal, state, and local levels and foreign countries regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products.
» More Articles for ABIO

Headlines

Articles On GuruFocus.com
comment on ABIO Mar 15 2013 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

More From Other Websites
LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the... Sep 16 2014
LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific... Sep 08 2014
ARCA BIOPHARMA, INC. Financials Aug 22 2014
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2014
ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application Aug 18 2014
ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report Aug 13 2014
ARCA Biopharma: An Undervalued Biotech With A Bright Future Jul 03 2014
ARCA BIOPHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other... Jun 09 2014
Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors Jun 09 2014
5 Stocks Under $10 Set to Soar May 29 2014
ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report May 13 2014
ARCA biopharma to Present at the Growth Capital Expo 2014 Apr 22 2014
ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro... Apr 17 2014
ARCA biopharma Files Shelf Registration Statement Apr 04 2014
Checking In On ARCA Biopharma Mar 25 2014
ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report Mar 20 2014
ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk... Mar 19 2014
Small-Cap Biotech on the Verge of a Breakout: ABIO Mar 12 2014
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 03 2014
4 Biotech Stocks Under $10 Moving Higher Feb 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK